Monte Rosa Therapeutics, Inc. Income (Loss) from Continuing Operations, Per Basic Share
Monte Rosa Therapeutics, Inc. (GLUE) reported Income (Loss) from Continuing Operations, Per Basic Share of -$0.43 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerBasicShare · last filed 2026-08-06
- Monte Rosa Therapeutics, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2026-06-30 was -$0.43.
- Monte Rosa Therapeutics, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2026-03-31 was -$0.45, a 178.95% decline year-over-year.
- Monte Rosa Therapeutics, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2025-09-30 was -$0.33.
- Monte Rosa Therapeutics, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2025-06-30 was -$0.15.
- Monte Rosa Therapeutics, Inc. income (loss) from continuing operations, per basic share for fiscal 2025 was -$0.46.
- Monte Rosa Therapeutics, Inc. income (loss) from continuing operations, per basic share for fiscal 2024 was -$0.98.
- Monte Rosa Therapeutics, Inc. income (loss) from continuing operations, per basic share for fiscal 2023 was -$2.63.
- Monte Rosa Therapeutics, Inc. income (loss) from continuing operations, per basic share for fiscal 2022 was -$2.30.
| Period end | Income (Loss) from Continuing Operations, Per Basic Share 3 month | Income (Loss) from Continuing Operations, Per Basic Share 6 month | Income (Loss) from Continuing Operations, Per Basic Share 9 month | Income (Loss) from Continuing Operations, Per Basic Share 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.43 10-Q · filed 2026-08-06 | -$0.87 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | -$0.45 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | -$0.46 10-K · filed 2026-03-17 | |||
| 2025-09-30 | -$0.33 10-Q · filed 2025-11-06 | $0.09 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | -$0.15 10-Q · filed 2026-08-06 | $0.42 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $0.57 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | -$0.98 10-K · filed 2026-03-17 | |||
| 2024-09-30 | -$0.29 10-Q · filed 2025-11-06 | -$1.21 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | -$0.43 10-Q · filed 2025-08-07 | -$0.95 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | -$0.53 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$2.63 10-K · filed 2025-03-20 | |||
| 2023-09-30 | -$0.70 10-Q · filed 2024-11-07 | -$2.06 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | -$0.71 10-Q · filed 2024-08-08 | -$1.36 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | -$0.65 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | -$2.30 10-K · filed 2024-03-14 | |||
| 2022-09-30 | -$0.58 10-Q · filed 2023-11-09 | -$1.67 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | -$0.57 10-Q · filed 2023-08-10 | -$1.08 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | -$0.51 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | -$2.96 10-K · filed 2023-03-16 | |||
| 2021-09-30 | -$0.43 10-Q · filed 2022-11-10 | -$2.85 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | -$3.63 10-Q · filed 2022-08-11 | -$9.03 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |